This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
Category: Forschung
ALS App Europe Initiative: Connecting Digital Care and Research Across Europe
On June 23, 2026, the “ALS App Europe Initiative Meeting” will take place in Madrid as part of this year’s European ALS Conference (ENCALS ). This satellite meeting will bring together experts from clinical care, research, and digital medicine to discuss new opportunities for a Europe-wide networked ALS care system. At the heart of the…
The ALS pen – digital precision for ALS research
With the ALS pen, we are presenting a new project for the structured and quantifiable recording of hand motor skills in the course of amyotrophic lateral sclerosis (ALS) for the first time. Our aim is to record motor changes in the hand of people with ALS in a more differentiated and standardized way. To this…
The ALS app at the international ALS symposium in San Diego
On December 4, 2025, the ALS app will be presented at the“ALS App Europe Initiative Meeting” at the International Symposium on ALS/MND in San Diego (USA). The meeting brings together European and American ALS centers, researchers and patient initiatives. You can find out more about the program here: https://symposium.mndassociation.org/programme/satellite-meetings/ The “ALS App Europe Initiative” meeting…
The new ALS-OPM classification is now in the ALS app.
We are pleased to introduce an important new feature in the ALS app today: The new OPM classification is now live! The OPM classification has been available in the current app version 5.10.4 for iOS (Apple) and Android (Google) since yesterday. What does the OPM classification mean? The phenotype of ALS – i.e. the individual…
Patient survey on THC:CBD in people with ALS
The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis (ALS), in which important findings on experience and satisfaction with treatment with cannabis-containing medicines containing tetrahydrocannabinol (THC) and cannabidiol (CBD) are obtained. Cannabis-containing treatment for ALS Medicines containing cannabis are used for severe illnesses when conventional medicines are not sufficiently…
Patient survey on eye control glasses for people with ALS
The patient survey on eye control glasses is a nationwide, systematic survey of patients with amyotrophic lateral sclerosis (ALS). The aim of the survey is to gain important insights into expectations of the eye-control glasses as well as experiences and satisfaction following treatment with the innovative aid. Drive the wheelchair safely with eye control glasses…
ALS Pharmacy Program Expands Its Network in Germany
The ALS Pharmacy Program is being further expanded with the addition of two new specialized pharmacies in Hanover and Quickborn. This development offers patients in these regions of Germany the opportunity to benefit from specialized care close to home. As a next step, the network of “ALS Pharmacies” is currently being expanded in southern Germany,…
Patient Survey on DMC in People with ALS
The DMC Patient Survey is a survey of patients with amyotrophic lateral sclerosis (ALS) that gathers important insights into their satisfaction with the DMC medication used to treat speech and swallowing difficulties. DMC Care for ALS Dextromethorphan/quinidine (DMC) is a medication used to treat speech and swallowing difficulties in patients with amyotrophic lateral sclerosis, with…
Patient Survey on PEG in People with ALS
The patient survey is a nationwide, systematic survey of 200 patients with amyotrophic lateral sclerosis (ALS), designed to gather important insights into patient satisfaction with percutaneous endoscopic gastrostomy (PEG) and medication administration via a PEG tube.Medication Administration via PEGPharmacotherapy for ALS is particularly complex when the disease is accompanied by progressive and severe swallowing difficulties…